AbbVie (US.ABBV)
Capital Allocation Audit · Period: 2010 – 2026
Key Metrics
US.ABBV · YoY: 2026 H1 vs 2025 H1
| Metric | Value | YoY |
|---|---|---|
| FCF Conversion | - | → |
| ROE | - | → |
| Cash Conversion | 0.0% | ↓ |
| D/E Ratio | - | → |
| Gross Margin | 73.4% | → |
US.ABBV (AbbVie) | YoY: 2026 H1 vs 2025 H1 Metric Value YoY --------------------------- FCF Conversion - → ROE - → Cash Conversion 0.0% ↓ D/E Ratio - → Gross Margin 73.4% →
Key Metrics
US.ABBV (AbbVie) | YoY: 2026 H1 vs 2025 H1
Metric Value YoY---------------------------FCF Conversion - →ROE - →Cash Conversion 0.0% ↓D/E Ratio - →Gross Margin 73.4% →Audit Dimensions
Unlimited Companies
AppleMicrosoftAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies